ID: ALA4872965

Max Phase: Preclinical

Molecular Formula: C41H43ClN8O5

Molecular Weight: 763.30

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  CN(c1ccc(C#N)c(Cl)c1)[C@H]1CC[C@H](NC(=O)c2ccc(N3CC(N4CCN(c5ccc6c(c5)C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C3)cc2)CC1

Standard InChI:  InChI=1S/C41H43ClN8O5/c1-46(30-9-4-26(22-43)35(42)21-30)28-10-5-27(6-11-28)44-38(52)25-2-7-29(8-3-25)49-23-32(24-49)48-18-16-47(17-19-48)31-12-13-33-34(20-31)41(55)50(40(33)54)36-14-15-37(51)45-39(36)53/h2-4,7-9,12-13,20-21,27-28,32,36H,5-6,10-11,14-19,23-24H2,1H3,(H,44,52)(H,45,51,53)/t27-,28-,36?

Standard InChI Key:  RNZSZCNUPQYOIX-RVWRWSNSSA-N

Associated Targets(Human)

Protein cereblon/Androgen receptor 263 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

VCaP 1078 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

LNCaP 8286 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 763.30Molecular Weight (Monoisotopic): 762.3045AlogP: 3.80#Rotatable Bonds: 8
Polar Surface Area: 149.40Molecular Species: NEUTRALHBA: 10HBD: 2
#RO5 Violations: 1HBA (Lipinski): 13HBD (Lipinski): 2#RO5 Violations (Lipinski): 2
CX Acidic pKa: 11.59CX Basic pKa: 6.88CX LogP: 4.32CX LogD: 4.20
Aromatic Rings: 3Heavy Atoms: 55QED Weighted: 0.32Np Likeness Score: -1.28

References

1. Xiang W, Zhao L, Han X, Qin C, Miao B, McEachern D, Wang Y, Metwally H, Kirchhoff PD, Wang L, Matvekas A, He M, Wen B, Sun D, Wang S..  (2021)  Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.,  64  (18.0): [PMID:34473519] [10.1021/acs.jmedchem.1c00900]

Source